参考文献/References:
[1] Craig WY,Neveux LM,Palomaki GE,et al. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies[J]. Clin Chem,1998,44(1):2301-2306.
[2] Danesh J,Collins R,Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies[J]. Circulation,2000,102(10):1082-1085.
[3] Erqou S,Kaptoge S,Perry PL,et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality[J]. JAMA,2009,302(4):412-423.
[4] Langsted A,Varbo A,Kamstrup PR,et al. Elevated?lipoprotein(a)?does?not?cause?low-grade?inflammation despite causal association with aortic valve stenosis and myocardial infarction: a study of 100,578 individuals from the general population[J]. Clin Endocrinol Metab,2015,100:2690-2699.
[5] Kamstrup PR,Benn M,Tybjaerg-Hansen A,et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study[J]. Circulation,2008,117(2):176-184.
[6] Kamstrup PR,Tybjaerg-Hansen A,Steffensen R,et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction[J]. JAMA, 2009,301(22):2331-2339.
[7] Tsimikas S. A test in context:lipoprotein(a) diagnosis,prognosis,controversies,and emerging therapies[J]. J Am Coll Cardiol,2017,69(6):692-711.
[8] Clarke R,Peden JF,Hopewell JC,et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease[J]. N Engl J Med,2009,361(26):2518-2528.
[9] Boffa MB,Koschinsky ML. Lipoprotein (a):truly a direct prothrombotic factor in cardiovascular disease?[J]. Lipid Res,2016,57(5):745-757.
[10] Graham MJ,Viney N,Crooke RM,et al. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans[J]. Lipid Res,2016,57(3):340-351.
[11] van der Valk FM,Bekkering S,Kroon J,et al. Oxidized phospholipids on lipoprotein(a)?elicit?arterial?wall?inflammation?and?an?inflammatory monocyte response in humans[J]. Circulation,2016,134(8):611-624.
[12] Nordestgaard BG,Chapman MJ,Ray K,et al. Lipoprotein(a) as a cardiovascular risk factor: current status[J]. Eur Heart J,2010,31(23):2844-2853.
[13] Catapano AL,Graham I,de Backer G,et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias[J]. Eur Heart J,2016,37(39):2999-3058.
[14] Tsimikas S. A Test in context:lipoprotein(a):diagnosis,prognosis,controversies,and emerging therapies[J]. J Am Coll Cardiol,2017,69(6),692-711.
[15] Marcovina SM,Albers JJ. Lipoprotein (a) measurements for clinical application[J]. J Lipid Res,2016,57(4):526-537.
[16] Kostner GM,Avogaro P,Cazzolato G,et al. Lipoprotein Lp(a) and the risk for myocardial infarction[J]. Atherosclerosis,1981,38(1-2):51-61.
[17] Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Emerging risk factors collaboration. lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality[J]. JAMA,2009,302(4):412-423.
[18] Kamstrup PR,Tybj?rg-Hansen A,Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction[J]. J Am Coll Cardiol,2013,61(11):1146-1156.
[19]Nordestgaard BG,Chapman MJ,Ray K,et al. Lipoprotein(a) as a cardiovascular risk factor: current status[J]. Eur Heart J,2010,31(23):2844-2853.
[20] Khera AV,Everett BM,Caulfield MP,et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)[J]. Circulation,2014, 129(6):635-642.
[21] Albers JJ,Slee A,O’Brien KD,et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High triglyceride and impact on global health outcomes)[J]. J Am Coll Cardiol,2013,62(17):1575-1579.
[22] Anderson TJ,Grégoire J,Pearson GJ,et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult [J]. Can J Cardiol,2016,32(11):1263-1282.
[23] von Eckardstein A. Will you, nill you, I will treat you: the taming of lipoprotein(a)[J]. Eur Heart J,2017,38(20):1570-1572.
[24] Yeang C,Hung MY,Byun YS,et al. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)[J]. J Clin Lipidol,2016,10(3):594–603. PMID:27206947
[25] Yeang C,Witztum JL,Tsimikas S. ‘LDL-C’=LDL-C+Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering[J]. Curr Opin Lipidol,2015,26(3):169-178.
[26] Tsimikas S,Viney NJ,Hughes SG,et al. Antisense therapy targeting apolipoprotein(a): a randomised,double-blind,placebo-controlled phase 1 study[J]. Lancet,2015, 386(10002):1472-1483.
[27] Viney NJ,van Capelleveen JC,Geary RS,et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials[J]. Lancet,2016,388(10057):2239-2253.
[28] Moriarty PM,Hemphill L. Lipoprotein apheresis[J]. Endocrinol Metab Clin North Am,2016, 45(1):39-54.
[29] Roeseler E,Julius U,Heigl F,et al. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization[J]. Arterioscler Thromb Vasc Biol,2016,36(9):2019-2027.
[30] Stein EA,Swergold GD. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics [J]. Curr Atheroscler Rep,2013,15(3):310.
[31] Raal FJ,Giugliano RP,Sabatine MS,et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phaseⅡ trials[J]. J Am Coll Cardiol,2014,63(13):1278-1288.
[32] Sabatine MS,Giugliano RP,Keech AC,et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med,2017,376(18):1713-1722.
[33] Lloyd-Jones DM,Morris PB,Ballantyne CM,et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on clinical expert consensus documents[J]. J Am Coll Cardiol,2016,68(1):92-125.
[34] Saeed A,Virani SS,Jones PH,et al. A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: a lipid clinic experience[J]. J Clin Lipidol,2017,11(3),596-599.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(8):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(8):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(8):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(8):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(8):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(8):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(8):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(8):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
[11]林琳 李京秀 闫娜 刘丹阳 查理 金恩泽.脂蛋白a的治疗现状及研究新方向[J].心血管病学进展,2021,(6):543.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.016]
LIN Lin,LI Jingxiu,YAN Na,et al.The Therapeutic Status and Research Prospects of the Treatment of Lipoprotein a[J].Advances in Cardiovascular Diseases,2021,(8):543.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.016]